scispace - formally typeset
Open AccessJournal ArticleDOI

ACE2, the Counter-Regulatory Renin-Angiotensin System Axis and COVID-19 Severity.

Reads0
Chats0
TLDR
In this article, the relationship between ACE2 expression and function in the lungs and other organs and COVID-19 severity was discussed and the effect of ACE2 upregulation with renin-angiotensin-aldosterone system inhibitors (RAASi) counterbalances the risks due to counterregulatory RAS axis amplification.
Abstract
Angiotensin (ANG)-converting enzyme (ACE2) is an entry receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19). ACE2 also contributes to a deviation of the lung renin-angiotensin system (RAS) towards its counter-regulatory axis, thus transforming harmful ANG II to protective ANG (1-7). Based on this purported ACE2 double function, it has been put forward that the benefit from ACE2 upregulation with renin-angiotensin-aldosterone system inhibitors (RAASi) counterbalances COVID-19 risks due to counter-regulatory RAS axis amplification. In this manuscript we discuss the relationship between ACE2 expression and function in the lungs and other organs and COVID-19 severity. Recent data suggested that the involvement of ACE2 in the lung counter-regulatory RAS axis is limited. In this setting, an augmentation of ACE2 expression and/or a dissociation of ACE2 from the ANG (1-7)/Mas pathways that leaves unopposed the ACE2 function, the SARS-CoV-2 entry receptor, predisposes to more severe disease and it appears to often occur in the relevant risk factors. Further, the effect of RAASi on ACE2 expression and on COVID-19 severity and the overall clinical implications are discussed.

read more

Citations
More filters
Journal ArticleDOI

Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets.

TL;DR: In this article, a review of the possible mechanisms of the host response following SARS-CoV-2 infection and surveyed current research conducted by in-vitro, in vivo and human observations, as well as existing suggestions.
Journal ArticleDOI

Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets

TL;DR: In this paper , a review of the possible mechanisms of the host response following SARS-CoV-2 infection and surveyed current research conducted by in vitro, in vivo and human observations, as well as existing suggestions.
Journal ArticleDOI

A Natural Plant Source-Tea Polyphenols, a Potential Drug for Improving Immunity and Combating Virus

TL;DR: TP can improve the disorder of flora, reduce the occurrence of cytokine storm, improve immunity, and prevent COVID-19 infection, and may be regarded as a potential and valuable source of new antiviral drugs with high efficiency and low toxicity.
Journal ArticleDOI

Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern

TL;DR: Wang et al. as mentioned in this paper developed a specific antibody against human ACE2 named hACE2.16, an anti-ACE2 antibody that recognizes and blocks ACE2-RBD binding without affecting ACE2 enzymatic activity.
Journal ArticleDOI

Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic

TL;DR: In this article , the authors summarize the latest insights into the complexity and interplay of the counter-regulatory RAS axis in hypertension, highlight the pathophysiological functions of ACE2, a multifunctional molecule linking hypertension and COVID-19, and discuss the function and therapeutic potential of targeting this counterregulatory rAS axis to prevent and treat hypertension in the context of the current COVID19 pandemic.
References
More filters
Journal ArticleDOI

Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection.

TL;DR: Wang et al. as mentioned in this paper performed a retrospective analysis of clinical parameters from 85 patients with laboratory-confirmed coronavirus disease 2019 (COVID-19); moreover, kidney histopathology from six additional COVID-2019 patients with post-mortem examinations was performed.
Journal ArticleDOI

Mineralocorticoid Receptor Blocker Increases Angiotensin-Converting Enzyme 2 Activity in Congestive Heart Failure Patients

TL;DR: Aldosterone antagonist action reduced oxidative stress, decreased ACE activity, and increased ACE2 activity, suggesting a protective role for MRB by possibly increasing generation of angiotensin (1–7) and decreasing formation of ang Elliotensin II.
Journal ArticleDOI

Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits.

TL;DR: It is suggested that diabetes and related traits may increase ACE2 expression, which may influence susceptibility to infection (or more severe infection), however, none of these findings withstood rigorous multiple testing corrections.
Related Papers (5)